CEL SCI CORP (CVM) Form 10-Q — May 15, 2026
CEL-SCI Corporation reported a net loss of $10.9 million for the six months ended March 31, 2026, with cash reserves declining to $1.9 million. The filing includes a going-concern warning, stating there is substantial doubt about the company's ability to continue as a going concern due to recurring losses and future liquidity needs. The company disclosed material weaknesses in its internal control over financial reporting, noting that disclosure controls were not effective as of March 31, 2026. Research and development expenses totaled $7.4 million, primarily driven by the development of its lead candidate Multikine for head and neck cancer.
Key figures
- Total Assets
- 17707274
- Cash Position
- 1890732
- Shares Outstanding
- 8493111
- Rd Expense6 M
- 7444145
- Finance Lease Liability
- 6847000
- Operating Lease Liability
- 1664000
- Subsequent Offering Price
- 1.2
- Subsequent Offering Shares
- 6000000
- Subsequent Offering Proceeds
- 7200000
Price after filing
Close on the filing date to close N calendar days later (from $1.30). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.